Structure Therapeutics reported positive mid-stage results from its Phase II ACCESS program for oral GLP-1 candidate aleniglipron, sending the company’s stock sharply higher. The company disclosed a placebo‑adjusted mean weight loss of 11.3% at 36 weeks for the 120 mg dose, driving a >100% share surge as investors priced an emerging oral competitor to Novo Nordisk and Eli Lilly. The data were presented amid an industry push for oral GLP‑1s: Novo Nordisk and Lilly move forward with oral formulations and regulatory priorities (including FDA priority vouchers) that could compress timelines. Structure’s result demonstrates a clinically meaningful weight-loss signal for a smaller developer and highlights near‑term competitive dynamics in anti‑obesity therapeutics. Clinicians and payors will watch durability, safety and how oral candidates differentiate from injectable standards of care.